Search

Your search keyword '"Yau, T."' showing total 790 results
Start Over Author "Yau, T."
790 results on '"Yau, T."'

3. 53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma

Author

Pollack, S., primary, Conley, A.P., additional, Tap, W.D., additional, Yen, C-C., additional, Charlson, J., additional, Davis, L., additional, Chalmers, A., additional, Druta, M., additional, Loggers, E., additional, Grewal, J.S., additional, Falchook, G., additional, Schulte, B., additional, Yau, T., additional, Kim, A., additional, Loong, H.H.F., additional, George, S., additional, Setty, B., additional, Mascarenhas, L., additional, Cote, G.M., additional, and Wilky, B., additional

Published
2024
Full Text
View/download PDF

5. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

Author

El-Khoueiry, A.B., primary, Trojan, J., additional, Meyer, T., additional, Yau, T., additional, Melero, I., additional, Kudo, M., additional, Hsu, C., additional, Kim, T.-Y., additional, Choo, S.-P., additional, Kang, Y.-K., additional, Yeo, W., additional, Chopra, A., additional, Soleymani, S., additional, Yao, J., additional, Neely, J., additional, Tschaika, M., additional, Welling, T.H., additional, and Sangro, B., additional

Published
2023
Full Text
View/download PDF

7. Replication study of SNP associations for colorectal cancer in Hong Kong Chinese

Author

Ho, JW, Choi, S-C, Lee, Y-F, Hui, TC, Cherny, SS, Garcia-Barceló, M-M, Carvajal-Carmona, L, Liu, R, To, S-H, Yau, T-K, Chung, CC, Yau, CC, Hui, SM, Lau, PY, Yuen, C-H, Wong, Y-W, Ho, S, Fung, SS, Tomlinson, IP, Houlston, RS, Cheng, KK, and Sham, PC

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Aging, Digestive Diseases, Prevention, Genetics, Human Genome, Cancer, Colo-Rectal Cancer, Aged, Case-Control Studies, Colorectal Neoplasms, Female, Hong Kong, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, colorectal cancer, genetic, association, replication, Chinese, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundRecent genome-wide association studies of colorectal cancer (CRC) have identified common single-nucleotide polymorphisms (SNPs) mapping to 10 independent loci that confer modest increased risk. These studies have been conducted in European populations and it is unclear whether these observations generalise to populations with different ethnicities and rates of CRC.MethodsAn association study was performed on 892 CRC cases and 890 controls recruited from the Hong Kong Chinese population, genotyping 32 SNPs, which were either associated with CRC in previous studies or are in close proximity to previously reported risk SNPs.ResultsTwelve of the SNPs showed evidence of an association. The strongest associations were provided by rs10795668 on 10p14, rs4779584 on 15q14 and rs12953717 on 18q21.2. There was significant linear association between CRC risk and the number of independent risk variants possessed by an individual (P=2.29 × 10(-5)).ConclusionThese results indicate that some previously reported SNP associations also impact on CRC risk in the Chinese population. Possible reasons for failure of replication for some loci include inadequate study power, differences in allele frequency, linkage disequilibrium structure or effect size between populations. Our results suggest that many associations for CRC are likely to generalise across populations.

Published
2011

11. 83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author

Chan, S.L., primary, Kudo, M., additional, Sangro, B., additional, Kelley, R.K., additional, Furuse, J., additional, Park, J-W., additional, Sunpaweravong, P., additional, Fasolo, A., additional, Yau, T., additional, Kawaoka, T., additional, Cheng, A-L., additional, Azevedo, S., additional, Reig Monzon, M.E., additional, Assenat, E., additional, Yarchoan, M., additional, He, A.R., additional, Makowsky, M., additional, Ran, D., additional, Negro, A., additional, and Abou-Alfa, G.K., additional

Published
2022
Full Text
View/download PDF

12. 67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author

Chan, S.L., primary, Kudo, M., additional, Sangro, B., additional, Kelley, R.K., additional, Furuse, J., additional, Park, J-W., additional, Sunpaweravong, P., additional, Fasolo, A., additional, Yau, T., additional, Kawaoka, T., additional, Cheng, A-L., additional, Azevedo, S., additional, Reig Monzon, M.E., additional, Assenat, E., additional, Yarchoan, M., additional, He, A.R., additional, Makowsky, M., additional, Gupta, C., additional, Negro, A., additional, and Abou-Alfa, G.K., additional

Published
2022
Full Text
View/download PDF

13. 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Author

Chan, L.S., primary, Kudo, M., additional, Sangro, B., additional, Kelley, R.K., additional, Furuse, J., additional, Park, J-W., additional, Sunpaweravong, P., additional, Fasolo, A., additional, Yau, T., additional, Kawaoka, T., additional, Cheng, A-L., additional, Azevedo, S., additional, Reig Monzon, M.E., additional, Assenat, E., additional, Yarchoan, M., additional, He, A.R., additional, Makowsky, M., additional, Ran, D., additional, Negro, A., additional, and Abou-Alfa, G.K., additional

Published
2022
Full Text
View/download PDF

14. 713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240

Author

Edeline, J., primary, Finn, R.S., additional, Bouattour, M., additional, Cheng, A-L., additional, Chan, S.L., additional, Yau, T., additional, Garrido, M., additional, Knox, J., additional, Daniele, B., additional, Breder, V., additional, Lim, H.Y., additional, Ogasawara, S., additional, Odeleye-Ajakaye, A., additional, Martinez-Forero, I., additional, Siegel, A.B., additional, and Merle, P., additional

Published
2022
Full Text
View/download PDF

15. STOP— a training intervention to optimise treatment for smoking cessation in community pharmacies: cluster randomised controlled trial

Author

Jumbe, S, Madurasinghe, VW, James, WY, Houlihan, C, Jumbe, SL, Yau, T, Tomini, F, Eldridge, S, Mihaylova, B, Steed, L, Sohanpal, R, Attar, D, Taylor, SJC, Griffiths, C, and Walton, R

Subjects
Adult, Pharmacies, Smokers, Smoking, Humans, Smoking Cessation, General Medicine, Self Efficacy
Abstract

Background Community pharmacies serve people with high levels of tobacco-related illness, but throughput in NHS Stop Smoking Services in pharmacies remains relatively low. We investigated the effectiveness of a complex intervention to increase service uptake and retention. Methods We randomised 60 pharmacies in England and Wales to the STOP intervention or usual practice in a pragmatic, parallel-group, controlled trial over 11 months. Smokers were blind to the allocation. The intervention was theory-based consultation skills training for pharmacy staff with environmental prompts (badges, calendars and behavioural cues). The primary outcome was the number of smokers attending an initial consultation and setting a quit date. Results The intervention made no significant difference in setting a quit date, retention or quit rate. A total of 631 adult smokers (service users) enrolled and set a quit date in intervention pharmacies compared to 641 in usual practice pharmacies, a rate ratio of 0.75 (95% CI 0.46 to 1.23) adjusted for site and number of prescriptions. A total of 432 (68%) service users were retained at 4 weeks in intervention and 500 (78%) in usual practice pharmacies (odds ratio 0.80, 0.41 to 1.55). A total of 265 (42%) service users quit smoking at 4 weeks in intervention and 276 (43%) in usual practice pharmacies (0.96, 0.65 to 1.43). The pharmacy staff were positive about the intervention with 90% (56/62) stating that it had improved their skills. Sixty-eight per cent would strongly recommend the training to others although there was no difference in self-efficacy for service delivery between arms. Seventy of 131 (53%) service users did not complete the 6-month follow-up assessment. However, 55/61 (90%) service users who completed follow-up were satisfied or very satisfied with the service. All usual practice arm service users (n = 33) and all but one in the intervention arm (n = 27) would recommend the service to smokers. Conclusions We found high levels of retention and acceptable quit rates in the NHS pharmacy stop smoking service. Despite pharmacy staff providing positive feedback on the STOP intervention, it made no difference to service throughput. Thus, other factors may currently limit service capacity to help smokers to quit. Trial registration ISRCTN, ISRCTN16351033. Retrospectively registered.

Published
2022

16. SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040

Author

Melero, I., primary, Yau, T., additional, Kang, Y., additional, Kim, T., additional, Santoro, A., additional, Sangro, B., additional, Kudo, M., additional, Hou, M., additional, Matilla, A., additional, Tovoli, F., additional, Knox, J., additional, He, A., additional, El-Rayes, B., additional, Acosta-Rivera, M., additional, Lim, H., additional, Soleymani, S., additional, Yao, J., additional, Neely, J., additional, Tschaika, M., additional, Hsu, C., additional, and El-Khoueiry, A., additional

Published
2022
Full Text
View/download PDF

17. SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study

Author

Vogel, A., primary, Edeline, J., additional, Ogasawara, S., additional, Kudo, M., additional, Finn, R., additional, Palmer, D., additional, Verslype, C., additional, Zagonel, V., additional, Fartoux, L., additional, Sarker, D., additional, Verset, G., additional, Chan, S., additional, Knox, J., additional, Cheng, A., additional, Daniele, B., additional, Yau, T., additional, Wang, A., additional, Hatogai, K., additional, Siegel, A., additional, and Cattan, S., additional

Published
2022
Full Text
View/download PDF

18. A Real Circuit Breaker: Hyperhemolysis Syndrome Related to the VA-ECMO Circuit?

Author

Pi, L., primary, Wang, V.N., additional, Aleksova, N., additional, Luk, A.C., additional, Posada, J. G. Duero, additional, Patriquin, C., additional, Dhamko, H., additional, Alvarez, J., additional, Yau, T., additional, Morris, I., additional, Hosseini-Moghaddam, S.M., additional, McDonald, M.A., additional, Cserti-Gazdewich, C., additional, and Moayedi, Y., additional

Published
2022
Full Text
View/download PDF

21. VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Author

Kelley, R.K., primary, Yau, T., additional, Cheng, A.-L., additional, Kaseb, A., additional, Qin, S., additional, Zhu, A.X., additional, Chan, S., additional, Sukeepaisarnjaroen, W., additional, Breder, V., additional, Verset, G., additional, Gane, E., additional, Borbath, I., additional, Gomez Rangel, J.D., additional, Merle, P., additional, Benzaghou, F.M., additional, Banerjee, K., additional, Hazra, S., additional, Fawcett, J., additional, and Rimassa, L., additional

Published
2022
Full Text
View/download PDF

23. 138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

Author

Bishnoi, S., primary, Yau, T., additional, Cosman, R., additional, Aghmesheh, M., additional, Moore, M., additional, Chan, S.L., additional, Mant, A., additional, Eek, R., additional, Zielinski, R., additional, Li, P., additional, Wang, H., additional, Ma, Y., additional, and Tse, A., additional

Published
2021
Full Text
View/download PDF

26. 981P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

Author

Bishnoi, S., primary, Cosman, R., additional, Moore, M., additional, Eek, R., additional, Mant, A., additional, Zielinski, R., additional, Chan, L.S., additional, Ma, Y., additional, Zhang, Q., additional, Yau, T., additional, Aghmesheh, M., additional, and Tse, A.N., additional

Published
2021
Full Text
View/download PDF

29. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study

Author

Pinter non-author presenter, M, additional, Finn, R, additional, De Toni, E, additional, Chung Cheung Yau, T, additional, Yen, C, additional, Hsu, C, additional, Chan, S, additional, He, A, additional, Galle, P, additional, Trojan, J, additional, Stirnimann, G, additional, Baron, A, additional, Acosta-Rivera, M, additional, Goyal, L, additional, Wang, C, additional, Abada, P, additional, Widau, R, additional, and Zhu, A, additional

Published
2021
Full Text
View/download PDF

32. 100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)

Author

Chan, S.L., Finn, R.S., Valle, J.W., Kelley, R.K., Yoo, C., Furuse, J., Ren, Z., Yau, T., Klumpen, H.J., Ozaka, M., Verslype, C., Bouattour, M., Park, J.O., Edeline, J., Ueno, M., Vogel, A., Yu, L., Malhotra, U., Siegel, A.B., and Qin, S.

Published
2023
Full Text
View/download PDF

33. O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study

Author

Cheng, A.-L., Cornelio, G., Shen, L., Price, T., Yang, T.-S., Chung, I.-J., Dai, G.-H., Lin, J.-K., Sharma, A., Yeh, K.-H., Ma, B., Zaatar, A., Guan, Z.-Z., Masood, N., Srimuninnimit, V., Yau, T., Beier, F., Chatterjee, S., and Lim, R.

Published
2016
Full Text
View/download PDF

35. Abstract No. 117 A phase 3, double-blind, randomized study of nivolumab and Ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma

Author

Sangro, B., primary, Harding, J., additional, Johnson, M., additional, Palmer, D., additional, Edeline, J., additional, Abou-Alfa, G., additional, Cheng, A., additional, Decaens, T., additional, El-Khoueiry, A., additional, Finn, R., additional, Galle, P., additional, Park, J., additional, Yau, T., additional, Begic, D., additional, Shen, Y., additional, Neely, J., additional, Sama, A., additional, and Kudo, M., additional

Published
2021
Full Text
View/download PDF

41. 46O Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial

Author

Dai, M.S., primary, Feng, Y.H., additional, Chen, S.W., additional, Masuda, N., additional, Sangai, T., additional, Yau, T., additional, Kwong, A., additional, Ngan, R., additional, Yap, Y.S., additional, Ang, P.C.S., additional, Ow, S., additional, Lee, K.S., additional, Kim, S.B., additional, Chung, H.C., additional, Keyvanjah, K., additional, Bebchuk, J., additional, and Chen, M-C.J., additional

Published
2020
Full Text
View/download PDF

49. O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

Author

Kelley, R., primary, Kudo, M., additional, Harris, W., additional, Ikeda, M., additional, Okusaka, T., additional, Kang, Y., additional, Qin, S., additional, Tai, D., additional, Lim, H., additional, Yau, T., additional, Yong, W., additional, Cheng, A., additional, Gasbarrini, A., additional, de Braud, F., additional, Bruix, J., additional, Borad, M., additional, Standifer, N., additional, He, P., additional, Negro, A., additional, Vlahovic, G., additional, Sangro, B., additional, and Abou-Alfa, G., additional

Published
2020
Full Text
View/download PDF

50. O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study

Author

Yau, T., primary, Hsu, C., additional, Kang, Y., additional, Kim, T., additional, Hou, M., additional, Lim, H., additional, Chao, Y., additional, Kim, Y., additional, Ikeda, M., additional, Choo, S., additional, Neely, J., additional, Shen, Y., additional, Tschaika, M., additional, and Kudo, M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results